Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aquivia Health vs FuturHealth

Aquivia Health
Graded #81

Higher grade

vs+6.6000000000000085
FuturHealth
Graded #215

Lower grade

The verdict

Aquivia Health takes it — 72.2/100 to 65.6/100.

Aquivia Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aquivia Health is a clinician-led, self-pay telehealth platform offering compounded GLP-1 therapy with the option to step up to branded Ozempic or Zepbound — an unusual side-by-side most compounded…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAquivia Health +26
86
60
Dose & formulationAquivia Health +4
85
81
Clinical oversightFuturHealth +3
64
67
Labs & monitoringFuturHealth +8
53
61
FulfillmentAquivia Health +9
71
62
Contract termsEven
55
55
Aquivia Health · left barFuturHealth · right bar

The numbers

MetricAquivia HealthFuturHealth
WeighScore72.2/10065.6/100
GradeCC
Scorecard rank#81#215
Semaglutide$149/mo$199/mo (compounded)
Tirzepatide$179/moNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
Aquivia Health

Graded #81 · C

Strengths

  • Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
  • Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
  • Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
  • Both compounded and branded GLP-1s offered side by side — unusual for a compounded provider
  • Self-pay model with no insurance required and no separate consultation fee

Where it loses points

  • No public list of states served — you must complete intake to learn if your state qualifies
  • No named 503A compounding pharmacy partner, limiting licensure verification
  • No LegitScript, PCAB, or BBB trust badges visible
  • Brand confusion: site schema names 'CatalystMD' while the customer-facing brand is Aquivia Health
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard